Clinical Trial

Efficacy and Safety of NVX-CoV2705

Study acronym: COVID-19
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-17; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-05-01
Trial Details
NCT Number NCT07086222
Lead Sponsor Novavax
Collaborators: Sanofi
Conditions COVID-19, Sars-CoV-2 Infection
Enrollment 6,500 participants
Start Date 2025-11-20
Primary Completion 2026-11-18 (estimated)
Study Completion 2026-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-05-08